Monogenic autoinflammatory diseases: Cytokinopathies

Cytokine

Volumn 74, Issue 2, 2015, Pages 237-246

  Moghaddas, Fiona ^a,b   Masters, Seth L ^a,b  

^a WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

Autoinflammatory; Inflammasome; Inflammasomopathy; Interferonopathy

Indexed keywords

CYTOKINE; INTERFERON; INTERLEUKIN 1; INTERLEUKIN 1 RECEPTOR A; INTERLEUKIN 10; INTERLEUKIN 36; PROTEIN MDA5; PROTEIN STING; TRANSCRIPTION FACTOR REL; UNCLASSIFIED DRUG; CARRIER PROTEIN; DEAD BOX PROTEIN; IFIH1 PROTEIN, HUMAN; IL10RB PROTEIN, HUMAN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 10 RECEPTOR ALPHA; INTERLEUKIN 10 RECEPTOR BETA; MEMBRANE PROTEIN; MPYS PROTEIN, HUMAN; NLRP3 PROTEIN, HUMAN;

AUTOINFLAMMATORY DISEASE; CONFORMATIONAL TRANSITION; CYTOKINE PRODUCTION; CYTOKINE RESPONSE; CYTOKINOPATHY; ENZYME ACTIVATION; GENE MUTATION; HUMAN; IMMUNE RESPONSE; NONHUMAN; PATHOPHYSIOLOGY; PHENOTYPE; PRIORITY JOURNAL; PROTEIN DEFECT; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; PROTEIN TARGETING; RECEPTOR DOWN REGULATION; REVIEW; SIGNAL TRANSDUCTION; ANIMAL; AUTOIMMUNE DISEASE; GENETIC DISORDER; GENETICS; IMMUNOLOGY; MUTATION;

ANIMALS; AUTOIMMUNE DISEASES; CARRIER PROTEINS; CYTOKINES; DEAD-BOX RNA HELICASES; GENETIC DISEASES, INBORN; HUMANS; INTERLEUKIN-10 RECEPTOR ALPHA SUBUNIT; INTERLEUKIN-10 RECEPTOR BETA SUBUNIT; MEMBRANE PROTEINS; MUTATION; NF-KAPPA B;

EID: 84941212400     PISSN: 10434666     EISSN: 10960023     Source Type: Journal    
DOI: 10.1016/j.cyto.2015.02.012     Document Type: Review

References (125)

1. Hawkins P.N., Lachmann H.J., McDermott M.F. Interleukin-1-receptor antagonist in the Muckle-Wells syndrome. N Engl J Med 2003, 348(25):2583-2584.
2. Hoffman H.M., et al. Mutation of a new gene encoding a putative pyrin-like protein causes familial cold autoinflammatory syndrome and Muckle-Wells syndrome. Nat Genet 2001, 29(3):301-305.
3. Sims J.E., Smith D.E. The IL-1 family: regulators of immunity. Nat Rev Immunol 2010, 10(2):89-102.
4. Garlanda C., Dinarello C.A., Mantovani A. The interleukin-1 family: back to the future. Immunity 2013, 39(6):1003-1018.
5. Henderson C., Goldbach-Mansky R. Monogenic IL-1 mediated autoinflammatory and immunodeficiency syndromes: finding the right balance in response to danger signals. Clin Immunol 2010, 135(2):210-222.
6. Bauernfeind F., Hornung V. Of inflammasomes and pathogens-sensing of microbes by the inflammasome. EMBO Mol Med 2013, 5(6):814-826.
7. Ozkurede V.U., Franchi L. Immunology in clinic review series; focus on autoinflammatory diseases: role of inflammasomes in autoinflammatory syndromes. Clin Exp Immunol 2012, 167(3):382-390.
8. Masters S.L., Aksentijevich I., Kastner D.L. Horror autoinflammaticus: the molecular pathophysiology of autoinflammatory disease. Annu Rev Immunol 2009, 27:621-668.
9. Agostini L., et al. NALP3 forms an IL-1beta-processing inflammasome with increased activity in Muckle-Wells autoinflammatory disorder. Immunity 2004, 20(3):319-325.
10. Vitale A., et al. Biological treatments: new weapons in the management of monogenic autoinflammatory disorders. Mediators Inflamm 2013, 2013:939847.
11. Ter Haar N., et al. Treatment of autoinflammatory diseases: results from the Eurofever Registry and a literature review. Ann Rheum Dis 2013, 72(5):678-685.
12. Consortium F.F. A candidate gene for familial Mediterranean fever. Nat Genet 1997, 17(1):25-31.
13. TIF Consortium Ancient missense mutations in a new member of the RoRet gene family are likely to cause familial Mediterranean fever. Cell 1997, 90(4):797-807.
14. Chae J.J., et al. The B30.2 domain of pyrin, the familial Mediterranean fever protein, interacts directly with caspase-1 to modulate IL-1beta production. Proc Natl Acad Sci USA 2006, 103(26):9982-9987.
15. Papin S., et al. The SPRY domain of Pyrin, mutated in familial Mediterranean fever patients, interacts with inflammasome components and inhibits proIL-1beta processing. Cell Death Differ 2007, 14(8):1457-1466.
16. Chae J.J., et al. Targeted disruption of pyrin, the FMF protein, causes heightened sensitivity to endotoxin and a defect in macrophage apoptosis. Mol Cell 2003, 11(3):591-604.
17. Xu H., et al. Innate immune sensing of bacterial modifications of Rho GTPases by the Pyrin inflammasome. Nature 2014, 513(7517):237-241.
18. Canna S.W., et al. An activating NLRC4 inflammasome mutation causes autoinflammation with recurrent macrophage activation syndrome. Nat Genet 2014, 46(10):1140-1146.
19. Romberg N., et al. Mutation of NLRC4 causes a syndrome of enterocolitis and autoinflammation. Nat Genet 2014, 46(10):1135-1139.
20. Kitamura A., et al. An inherited mutation in NLRC4 causes autoinflammation in human and mice. J Exp Med 2014, 211(12):2385-2396.
21. Kofoed E.M., Vance R.E. Innate immune recognition of bacterial ligands by NAIPs determines inflammasome specificity. Nature 2011, 477(7366):592-595.
22. Py B.F., et al. Deubiquitination of NLRP3 by BRCC3 critically regulates inflammasome activity. Mol Cell 2013, 49(2):331-338.
23. Chen S., Sun B. Negative regulation of NLRP3 inflammasome signaling. Protein Cell 2013, 4(4):251-258.
24. Vande Walle L., et al. Negative regulation of the NLRP3 inflammasome by A20 protects against arthritis. Nature 2014, 512(7512):69-73.
25. Hofmann S.R., et al. Update: cytokine dysregulation in chronic nonbacterial osteomyelitis (CNO). Int J Rheumatol 2012, 2012:310206.
26. Latz E., Xiao T.S., Stutz A. Activation and regulation of the inflammasomes. Nat Rev Immunol 2013, 13(6):397-411.
27. Saleh M., et al. Differential modulation of endotoxin responsiveness by human caspase-12 polymorphisms. Nature 2004, 429(6987):75-79.
28. Ito S., Hara Y., Kubota T. CARD8 is a negative regulator for NLRP3 inflammasome, but mutant NLRP3 in cryopyrin-associated periodic syndromes escapes the restriction. Arthritis Res Ther 2014, 16(1):R52.
29. Lamkanfi M., et al. INCA, a novel human caspase recruitment domain protein that inhibits interleukin-1beta generation. J Biol Chem 2004, 279(50):51729-51738.
30. Druilhe A., et al. Regulation of IL-1beta generation by pseudo-ICE and ICEBERG, two dominant negative caspase recruitment domain proteins. Cell Death Differ 2001, 8(6):649-657.
31. Le H.T., Harton J.A. Pyrin- and CARD-only proteins as regulators of NLR functions. Front Immunol 2013, 4:275.
32. Khare S., et al. The PYRIN domain-only protein POP3 inhibits ALR inflammasomes and regulates responses to infection with DNA viruses. Nat Immunol 2014, 15(4):343-353.
33. Touitou I., et al. The expanding spectrum of rare monogenic autoinflammatory diseases. Orphanet J Rare Dis 2013, 8:162.
34. Stern S.M., Ferguson P.J. Autoinflammatory bone diseases. Rheum Dis Clin North Am 2013, 39(4):735-749.
35. Lipsker D. The Schnitzler syndrome. Orphanet J Rare Dis 2010, 5:38.
36. Loock J., et al. Genetic predisposition (NLRP3 V198M mutation) for IL-1-mediated inflammation in a patient with Schnitzler syndrome. J Allergy Clin Immunol 2010, 125(2):500-502.
37. Thonhofer R., Uitz E., Graninger W. Schnitzler's syndrome-exacerbation after anti-TNF treatment. Rheumatology (Oxford) 2007, 46(6):1041-1042.
38. Aikawa N.E., et al. Schnitzler's syndrome improvement after anti-TNF-alpha therapy. Joint Bone Spine 2010, 77(5):491.
39. Krause K., et al. Complete remission in 3 of 3 anti-IL-6-treated patients with Schnitzler syndrome. J Allergy Clin Immunol 2012, 129(3):848-850.
40. Migliorini P., et al. Free circulating interleukin-18 is increased in Schnitzler syndrome: a new autoinflammatory disease?. Eur Cytokine Netw 2009, 20(3):108-111.
41. Pizzirani C., et al. Dysfunctional inflammasome in Schnitzler's syndrome. Rheumatology (Oxford) 2009, 48(10):1304-1308.
42. Ferguson P.J., Sandu M. Current understanding of the pathogenesis and management of chronic recurrent multifocal osteomyelitis. Curr Rheumatol Rep 2012, 14(2):130-141.
43. Majeed H.A., et al. On mice and men: An autosomal recessive syndrome of chronic recurrent multifocal osteomyelitis and congenital dyserythropoietic anemia. J Pediatr 2000, 137(3):441-442.
44. Valdearcos M., et al. Lipin-2 reduces proinflammatory signaling induced by saturated fatty acids in macrophages. J Biol Chem 2012, 287(14):10894-10904.
45. Majeed H.A., et al. The syndrome of chronic recurrent multifocal osteomyelitis and congenital dyserythropoietic anaemia. Report of a new family and a review. Eur J Pediatr 2001, 160(12):705-710.
46. Herlin T., et al. Efficacy of anti-IL-1 treatment in Majeed syndrome. Ann Rheum Dis 2013, 72(3):410-413.
47. Gresnigt M.S., van de Veerdonk F.L. Biology of IL-36 cytokines and their role in disease. Semin Immunol 2013, 25(6):458-465.
48. Wang P., et al. The interleukin-1-related cytokine IL-1F8 is expressed in glial cells, but fails to induce IL-1beta signalling responses. Cytokine 2005, 29(6):245-250.
49. Li N., et al. Alarmin function of cathelicidin antimicrobial peptide LL37 through IL-36 gamma induction in human epidermal keratinocytes. J Immunol 2014, 193(10):5140-5148.
50. Towne J.E., et al. Interleukin-36 (IL-36) ligands require processing for full agonist (IL-36 alpha, IL-36 beta, and IL-36 gamma) or antagonist (IL-36Ra) activity. J Biol Chem 2011, 286(49):42594-42602.
51. Dietrich D., Gabay C. Inflammation: IL-36 has proinflammatory effects in skin but not in joints. Nat Rev Rheumatol 2014, 10(11):639-640.
52. Rossi-Semerano L., et al. First clinical description of an infant with interleukin-36-receptor antagonist deficiency successfully treated with anakinra. Pediatrics 2013, 132(4):e1043-e1047.
53. Tauber M., et al. Is it relevant to use an interleukin-1-inhibiting strategy for the treatment of patients with deficiency of interleukin-36 receptor antagonist?. Br J Dermatol 2014, 170(5):1198-1199.
54. Sugiura K., et al. Successful treatment with infliximab of sibling cases with generalized pustular psoriasis caused by deficiency of interleukin-36 receptor antagonist. J Eur Acad Dermatol Venereol 2014.
55. Korber A., et al. Mutations in IL36RN in patients with generalized pustular psoriasis. J Invest Dermatol 2013, 133(11):2634-2637.
56. Onoufriadis A., et al. Mutations in IL36RN/IL1F5 are associated with the severe episodic inflammatory skin disease known as generalized pustular psoriasis. Am J Hum Genet 2011, 89(3):432-437.
57. Glocker E.O., et al. Inflammatory bowel disease and mutations affecting the interleukin-10 receptor. N Engl J Med 2009, 361(21):2033-2045.
58. Saxena A., et al. Interleukin-10 paradox: A potent immunoregulatory cytokine that has been difficult to harness for immunotherapy. Cytokine 2014.
59. Hutchins A.P., Diez D., Miranda-Saavedra D. The IL-10/STAT3-mediated anti-inflammatory response: recent developments and future challenges. Brief Funct Genomics 2013, 12(6):489-498.
60. Yao Y., et al. IL-10-producing lymphocytes in inflammatory disease. Int Rev Immunol 2013, 32(3):324-336.
61. Saraiva M., O'Garra A. The regulation of IL-10 production by immune cells. Nat Rev Immunol 2010, 10(3):170-181.
62. Shim J.O., Seo J.K. Very early-onset inflammatory bowel disease (IBD) in infancy is a different disease entity from adult-onset IBD; one form of interleukin-10 receptor mutations. J Hum Genet 2014, 59(6):337-341.
63. Murugan D., et al. Very early onset inflammatory bowel disease associated with aberrant trafficking of IL-10R1 and cure by T cell replete haploidentical bone marrow transplantation. J Clin Immunol 2014, 34(3):331-339.
64. Hall J.C., Rosen A. Type I interferons: crucial participants in disease amplification in autoimmunity. Nat Rev Rheumatol 2010, 6(1):40-49.
65. Gonzalez-Navajas J.M., et al. Immunomodulatory functions of type I interferons. Nat Rev Immunol 2012, 12(2):125-135.
66. Ishikawa H., Barber G.N. The STING pathway and regulation of innate immune signaling in response to DNA pathogens. Cell Mol Life Sci 2011, 68(7):1157-1165.
67. Liu Y., et al. Activated STING in a vascular and pulmonary syndrome. N Engl J Med 2014, 371(6):507-518.
68. Crow Y.J. Type I interferonopathies: a novel set of inborn errors of immunity. Ann N Y Acad Sci 2011, 1238:91-98.
69. Rice G.I., et al. Mutations in ADAR1 cause Aicardi-Goutieres syndrome associated with a type I interferon signature. Nat Genet 2012, 44(11):1243-1248.
70. Hofer M.J., Campbell I.L. Type I interferon in neurological disease-the devil from within. Cytokine Growth Factor Rev 2013, 24(3):257-267.
71. Funabiki M., et al. Autoimmune disorders associated with gain of function of the intracellular sensor MDA5. Immunity 2014, 40(2):199-212.
72. Rice G.I., et al. Gain-of-function mutations in IFIH1 cause a spectrum of human disease phenotypes associated with upregulated type I interferon signaling. Nat Genet 2014, 46(5):503-509.
73. Oda H., et al. Aicardi-Goutieres syndrome is caused by IFIH1 mutations. Am J Hum Genet 2014, 95(1):121-125.
74. Briggs T.A., et al. Tartrate-resistant acid phosphatase deficiency causes a bone dysplasia with autoimmunity and a type I interferon expression signature. Nat Genet 2011, 43(2):127-131.
75. Lausch E., et al. Genetic deficiency of tartrate-resistant acid phosphatase associated with skeletal dysplasia, cerebral calcifications and autoimmunity. Nat Genet 2011, 43(2):132-137.
76. Setta-Kaffetzi N., et al. AP1S3 mutations are associated with pustular psoriasis and impaired Toll-like receptor 3 trafficking. Am J Hum Genet 2014, 94(5):790-797.
77. Mansouri B., Richards L., Menter A. Treatment of two patients with generalised pustular psoriasis with the interleukin-1 beta inhibitor gevokizumab. Br J Dermatol 2014.
78. Viguier M., et al. Successful treatment of generalized pustular psoriasis with the interleukin-1-receptor antagonist Anakinra: lack of correlation with IL1RN mutations. Ann Intern Med 2010, 153(1):66-67.
79. Ivashkiv L.B., Donlin L.T. Regulation of type I interferon responses. Nat Rev Immunol 2014, 14(1):36-49.
80. Zhang X., et al. Human intracellular ISG15 prevents interferon-alpha/beta over-amplification and auto-inflammation. Nature 2015, 517(7532):89-93.
81. Bogunovic D., et al. Mycobacterial disease and impaired IFN-gamma immunity in humans with inherited ISG15 deficiency. Science 2012, 337(6102):1684-1688.
82. Akira S., Uematsu S., Takeuchi O. Pathogen recognition and innate immunity. Cell 2006, 124(4):783-801.
83. Kawai T., Akira S. The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors. Nat Immunol 2010, 11(5):373-384.
84. Chen G.Y., Nunez G. Sterile inflammation: sensing and reacting to damage. Nat Rev Immunol 2010, 10(12):826-837.
85. McDermott A., et al. Proteasome-associated autoinflammatory syndromes: advances in pathogeneses, clinical presentations, diagnosis, and management. Int J Dermatol 2015, 54(2):121-129.
86. Martinon F., Aksentijevich I. New players driving inflammation in monogenic autoinflammatory diseases. Nat Rev Rheumatol 2015, 11(1):11-20.
87. Wouters C.H., et al. Blau syndrome, the prototypic auto-inflammatory granulomatous disease. Pediatr Rheumatol Online J 2014, 12:33.
88. Caso F., et al. Caveats and truths in genetic, clinical, autoimmune and autoinflammatory issues in Blau syndrome and early onset sarcoidosis. Autoimmun Rev 2014, 13(12):1220-1229.
89. Lupfer C., Kanneganti T.D. Unsolved mysteries in NLR biology. Front Immunol 2013, 4:285.
90. Zhong Y., Kinio A., Saleh M. Functions of NOD-like receptors in human diseases. Front Immunol 2013, 4:333.
91. Jeru I., et al. Mutations in NALP12 cause hereditary periodic fever syndromes. Proc Natl Acad Sci USA 2008, 105(5):1614-1619.
92. Vladimer G.I., et al. The NLRP12 inflammasome recognizes Yersinia pestis. Immunity 2012, 37(1):96-107.
93. Borghini S., et al. Clinical presentation and pathogenesis of cold-induced autoinflammatory disease in a family with recurrence of an NLRP12 mutation. Arthritis Rheum 2011, 63(3):830-839.
94. van der Burgh R., et al. Defects in mitochondrial clearance predispose human monocytes to interleukin-1beta hypersecretion. J Biol Chem 2014, 289(8):5000-5012.
95. Kuijk L.M., et al. HMG-CoA reductase inhibition induces IL-1β release through Rac1/PI3K/PKB-dependent caspase-1 activation. Blood 2008, 112:3563-3573.
96. Stoffels M., et al. TLR2/TLR4-dependent exaggerated cytokine production in hyperimmunoglobulinaemia D and periodic fever syndrome. Rheumatology (Oxford) 2015, 54(2):363-368.
97. Fuchs-Telem D., et al. Familial pityriasis rubra pilaris is caused by mutations in CARD14. Am J Hum Genet 2012, 91(1):163-170.
98. Yoshitaka T., et al. Enhanced TLR-MYD88 signaling stimulates autoinflammation in SH3BP2 cherubism mice and defines the etiology of cherubism. Cell Rep 2014, 8(6):1752-1766.
99. Mukai T., et al. SH3BP2 Cherubism Mutation potentiates TNF-alpha-induced osteoclastogenesis via NFATc1 and TNF-alpha-mediated inflammatory bone loss. J Bone Miner Res 2014, 29(12):2618-2635.
100. Hero M., et al. Anti-tumor necrosis factor treatment in cherubism-clinical, radiological and histological findings in two children. Bone 2013, 52(1):347-353.
101. Tokunaga F. Linear ubiquitination-mediated NF-kappaB regulation and its related disorders. J Biochem 2013, 154(4):313-323.
102. Tokunaga F., Iwai K. Linear ubiquitination: a novel NF-kappaB regulatory mechanism for inflammatory and immune responses by the LUBAC ubiquitin ligase complex. Endocr J 2012, 59(8):641-652.
103. Boisson B., et al. Immunodeficiency, autoinflammation and amylopectinosis in humans with inherited HOIL-1 and LUBAC deficiency. Nat Immunol 2012, 13(12):1178-1186.
104. Schulert G.S., Grom A.A. Pathogenesis of macrophage activation syndrome and potential for cytokine- directed therapies. Annu Rev Med 2015, 66:145-159.
105. Brisse E., Wouters C.H., Matthys P. Hemophagocytic lymphohistiocytosis (HLH): A heterogeneous spectrum of cytokine-driven immune disorders. Cytokine Growth Factor Rev 2014.
106. Grom A.A. Canakinumab for the treatment of systemic juvenile idiopathic arthritis. Expert Rev Clin Immunol 2014, 10(11):1427-1435.
107. Ruperto N., et al. Two randomized trials of canakinumab in systemic juvenile idiopathic arthritis. N Engl J Med 2012, 367(25):2396-2406.
108. De Benedetti F., et al. Randomized trial of tocilizumab in systemic juvenile idiopathic arthritis. N Engl J Med 2012, 367(25):2385-2395.
109. Durand M., et al. Macrophage activation syndrome treated with anakinra. J Rheumatol 2010, 37(4):879-880.
110. Kelly A., Ramanan A.V. A case of macrophage activation syndrome successfully treated with anakinra. Nat Clin Pract Rheumatol 2008, 4(11):615-620.
111. Miettunen P.M., et al. Successful treatment of severe paediatric rheumatic disease-associated macrophage activation syndrome with interleukin-1 inhibition following conventional immunosuppressive therapy: case series with 12 patients. Rheumatology (Oxford) 2011, 50(2):417-419.
112. Nigrovic P.A., et al. Anakinra as first-line disease-modifying therapy in systemic juvenile idiopathic arthritis: report of forty-six patients from an international multicenter series. Arthritis Rheum 2011, 63(2):545-555.
113. Yokota S., et al. Longterm safety and effectiveness of the anti-interleukin 6 receptor monoclonal antibody tocilizumab in patients with systemic juvenile idiopathic arthritis in Japan. J Rheumatol 2014, 41(4):759-767.
114. Banse C., et al. Reactive macrophage activation syndrome possibly triggered by canakinumab in a patient with adult-onset Still's disease. Joint Bone Spine 2013, 80(6):653-655.
115. Kobayashi M., et al. Benefit and a possible risk of tocilizumab therapy for adult-onset Still's disease accompanied by macrophage-activation syndrome. Mod Rheumatol 2011, 21(1):92-96.
116. Giannelou A., Zhou Q., Kastner D.L. When less is more: primary immunodeficiency with an autoinflammatory kick. Curr Opin Allergy Clin Immunol 2014, 14(6):491-500.
117. Ombrello M.J., et al. Cold urticaria, immunodeficiency, and autoimmunity related to PLCG2 deletions. N Engl J Med 2012, 366(4):330-338.
118. Zhou Q., et al. A hypermorphic missense mutation in PLCG2, encoding phospholipase Cgamma2, causes a dominantly inherited autoinflammatory disease with immunodeficiency. Am J Hum Genet 2012, 91(4):713-720.
119. Chae J.J., et al. Connecting two pathways through Ca signaling: NLRP3 inflammasome activation induced by a hypermorphic PLCG2 mutation. Arthritis Rheumatol 2014.
120. Molho-Pessach V., et al. The H syndrome is caused by mutations in the nucleoside transporter hENT3. Am J Hum Genet 2008, 83(4):529-534.
121. Melki I., et al. Mutation in the SLC29A3 gene: a new cause of a monogenic, autoinflammatory condition. Pediatrics 2013, 131(4):e1308-e1313.
122. Navon Elkan P., et al. Mutant adenosine deaminase 2 in a polyarteritis nodosa vasculopathy. N Engl J Med 2014, 370(10):921-931.
123. Zhou Q., et al. Early-onset stroke and vasculopathy associated with mutations in ADA2. N Engl J Med 2014, 370(10):911-920.
124. Zavialov A.V., Engstrom A. Human ADA2 belongs to a new family of growth factors with adenosine deaminase activity. Biochem J 2005, 391(Pt 1):51-57.
125. Zavialov A.V., et al. Structural basis for the growth factor activity of human adenosine deaminase ADA2. J Biol Chem 2010, 285(16):12367-12377.